Prostatype Genomics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Prostatype Genomics
Access all reports
Prostatype Genomics AB specializes in developing, manufacturing, and marketing the Prostatype genetic test, which assesses the aggressiveness of prostate cancer. The test aids clinicians and patients in making informed treatment decisions by minimizing both over- and under-treatment, thereby improving patient quality of life and optimizing healthcare resources. The Prostatype test uses genetic expression data from prostate biopsies combined with clinical parameters to predict cancer prognosis. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
PROGEN
Country
🇸🇪 Sweden